25 LLC’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

25 LLC’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-18	Closed	-$526	–	711
2023 Q1	$526	Buy	+18	New	+$534	﹤0.01%	330

Other funds holding EGRX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

25 LLC's EGRX Position: Q2 2023 in Review

25 LLC sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2023, closing a stake of 18 shares — an estimated $526 sold.

25 LLC first reported a position in EGRX in Q1 2023 and held it in 1 quarter. The position peaked at $526 in Q1 2023. 126 funds tracked by Wall St. Rank hold EGRX as of Q2 2023.

25 LLC reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
25 LLC sold 18 Eagle Pharmaceuticals, Inc. shares in Q2 2023, an estimated $526.
25 LLC first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2023 and held it in 1 quarter.
25 LLC's Eagle Pharmaceuticals, Inc. position peaked at $526 in Q1 2023.
126 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2023.

Based on 25 LLC's 13F filing for Q2 2023, filed 19 Jul 2023.